HOME >> BIOLOGY >> NEWS
Turning down the Sun

reduction in fossil fuels might entail.

"Teller and Wood are technical optimists, and pessimists about human behaviour," says Caldeira, who saw Wood present their work in 1998, and was disturbed by the re-emergence of these Sun-blocking proposals. "My hope was to show that it wouldn't work," he says, "so people would give up on it."

Caldeira thought he saw a central flaw in all of these Sun-dimming ideas. While reducing sunlight might have an overall cooling effect on the planet as a whole, he argued, it wouldn't counteract the local heating effect from CO2. The two forces act in a completely different way on different parts of the globe. The capacity of CO2 to trap heat increases with temperature, so it's more effective near the equator. The Sun, on the other hand, shines more in the northern hemisphere in June, more in the southern hemisphere in December. Surely, thought Caldeira, these very different phenomena couldn't exactly cancel each other out? Not on a country-sized scale, or over the different seasons. Instead, he expected the winters to get warmer and the summers cooler, the poles warmer and the tropics cooler. In short, many of the problems the Earth faces from global warming-the seasons becoming more and more alike, and a variety of weird weather (New Scientist, 16 September, p 26)-would be made worse.

To try to prove his hypothesis, Caldeira went to work with his colleague Bala Govindasamy and a hefty climate-modelling program. They invented three future worlds to test. In the first, the control model, levels of atmospheric CO2 were set at just 280 parts per million-the pre-industrial value-and the Sun shone at a constant 1367 watts per square metre at the Earth's surface. In the second, there was twice as much CO2, adding an extra 4.17 watts per square metre to the Earth-bound radiation. In the final, geoengineered scenario, the doubled CO2 was countered by cutting 1.8 per cent of the Sun's light, again worth 4.17 watts per square metre.
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
19-Sep-2000


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Turning bone into nerve
2. Turning foe into friend with lentiviral vectors
3. Turning off building lights reduces bird window-kill by 83%
4. Turning blood into brain: new studies suggest bone marrow stem cells can develop into neurons in living animals
5. Turning salt and water into wine
6. UNC Researchers Reduce Arthritis Severity By Turning Off Molecular Switch
7. Turning "Unrecyclable" Waste Into Plastic Products
8. Survey Shows Students Turning To Physicians Less As Drug Abuse Increases
9. Africa At The Turning Point
10. Nitric Oxide Found To Control Cells By Turning On Genes; Suggests New Role In Health And Disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology:
Cached News: